跳到正文
原文
Medical Xpress·· 2026-10-13AI 评分57

靶向放射性疗法可能有助于延缓复发前列腺癌的扩散

Targeted radioactive therapy may help delay spread of recurrent prostate cancer

AI 导读

研究显示,将靶向放射性药物177 Lu-PNT2002与立体定向体部放疗联合使用,可延缓前列腺癌复发和扩散,降低需要激素治疗的风险。

正文
radioactive therapy
Credit: Unsplash/CC0 Public Domain

Adding the targeted radioactive drug 177Lu-PNT2002 to stereotactic body radiation therapy, or SBRT, may help keep recurrent prostate cancer under control longer than SBRT alone, according to new research led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.

The team found patients who received the combination were less likely to develop widespread disease or hormone-resistant cancer, suggesting the treatment may offer benefits beyond delaying the initial return of the disease.

The findings, published in the journal European Urology, come from an updated analysis of the phase 2 LUNAR trial, which followed men for nearly three years after their prostate cancer had returned and was detected in a limited number of sites.

"Our earlier findings showed that adding 177Lu-PNT2002 could significantly delay progression and the need for hormone therapy," said Dr. Amar Kishan, executive vice chair of radiation oncology at the David Geffen School of Medicine at UCLA and first author of the study.

"But with longer follow-up, we're seeing signs that the benefit may extend beyond simply delaying recurrence, including a potential reduction in the risk of widespread disease and cancer that no longer responds to hormone therapy. These findings suggest we may be able to treat cancer cells that are present elsewhere in the body but are too small to detect, while giving patients more time before they need hormone therapy."

Targeting cancer too small to detect

For some men with prostate cancer, the disease returns after initial treatment and can be detected in only a few locations. Doctors can use SBRT to target and destroy those visible tumors. But cancer cells may also be present elsewhere in the body at levels too small to be detected even by highly sensitive PSMA PET scans.

Because 177Lu-PNT2002 travels through the bloodstream and targets PSMA, a protein found on most prostate cancer cells, the treatment may be able to reach some of this otherwise undetectable disease.

The approach could be particularly important for patients who want to delay hormone therapy. Although hormone therapy can control recurrent prostate cancer, long-term treatment can cause side effects and affect quality of life.

Testing the combination in recurrent disease

The LUNAR trial included 92 men with oligorecurrent hormone-sensitive prostate cancer, meaning their cancer had returned and spread to one to five sites that could be identified on PSMA PET/CT and treated with SBRT.

The patients were randomly assigned to receive either SBRT alone or two cycles of 177Lu-PNT2002 followed by SBRT. The cycles of radioactive treatment were given about eight weeks apart, with SBRT administered after the second cycle.

The researchers followed the patients for a median of 31.9 months. They evaluated progression-free survival, as well as several additional measures of how the cancer progressed, including whether patients developed more widespread disease, castration-resistant prostate cancer or progression on conventional imaging.

Lower progression risk with longer follow-up

The longer follow-up continued to show a benefit from adding 177Lu-PNT2002 to SBRT. The risk of progression or needing additional hormone therapy was 62% lower in the combination group than in the SBRT-alone group.

At 24 months, 33% of patients who received 177Lu-PNT2002 followed by SBRT had no detectable disease, compared with 12% of those who received SBRT alone.

The researchers also found fewer patients in the combination group developed widespread disease. Three patients receiving 177Lu-PNT2002 and SBRT developed more than five new cancer sites, compared with nine patients who received SBRT alone.

Similarly, one patient in the combination group developed castration-resistant prostate cancer, compared with seven patients in the SBRT-alone group. Because these were exploratory analyses with relatively few events, the findings will need to be confirmed in larger studies.

The combination also showed a trend toward longer control of disease on conventional imaging, which is used to detect larger or more established tumors.

In the earlier analysis of the trial, patients who received 177Lu-PNT2002 followed by SBRT went a median of 17.6 months without progression or the need for additional hormone therapy, compared with 7.4 months for those who received SBRT alone.

The researchers observed no new safety signals with longer follow-up, and serious treatment-related side effects remained uncommon.

Earlier treatment warrants further study

For patients whose prostate cancer has returned in only a few places, the goal of treatment is often to control the visible tumors while delaying the need for hormone therapy and preventing the cancer from spreading more widely.

The findings suggest that combining a treatment that targets visible tumors with a radioactive drug that travels throughout the body may offer a way to address both visible and microscopic disease.

"This is an important step toward understanding whether we can use these treatments earlier, when the amount of cancer in the body is still relatively small," Kishan said.

The researchers say the findings support further study of PSMA-targeted radioligand therapy earlier in the course of prostate cancer, before patients develop more advanced or treatment-resistant disease.

Publication details

Amar U. Kishan et al., 177Lu-Prostate-specific Membrane Antigen Prior to Stereotactic Ablative Radiotherapy in Oligorecurrent Prostate Cancer: Secondary and Exploratory End Point Results from the Randomized Phase 2 LUNAR Trial, European Urology (2026). DOI: 10.1016/j.eururo.2026.09.005

Journal information: European Urology

Clinical categories

OncologyMen's health

Who's behind this story?

Swati Mestri

Swati Mestri

Swati Mestri holds a bachelor's degree in Electronics Engineering and has worked as a content editor since 2019. She has experience editing research documents across technology, health care, and materials science, and has a particular interest in technology and space. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Targeted radioactive therapy may help delay spread of recurrent prostate cancer (2026, October 13) retrieved 13 October 2026 from https://medicalxpress.com/news/2026-10-radioactive-therapy-delay-recurrent-prostate.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com